Imunon, Inc. (then Celsion Corporation) — Q1 2012 Form 10-Q
Reporting period: Three months ended March 31, 2012; filed May 15, 2012. The filing identifies the registrant as Celsion Corporation, not Imunon. The company was a clinical-stage oncology drug developer, with ThermoDox as its lead candidate.
Financial results and position
| Metric | Q1 2012 | Q1 2011 / comparison |
|---|---|---|
| Revenue | $0 | $2.0 million licensing revenue |
| Research and development | $4.69 million | $4.35 million |
| General and administrative | $1.57 million | $1.22 million |
| Total operating expenses | $6.26 million | $5.56 million |
| Net loss | $6.19 million; $0.19 per share | $3.76 million; $0.28 per share |
| Cash used in operations | $5.73 million | $4.37 million |
| Cash and cash equivalents | $9.12 million | $20.15 million at Dec. 31, 2011 |
| Short-term investments | $15.47 million | $10.40 million at Dec. 31, 2011 |
| Working capital | $19.4 million | $25.3 million at Dec. 31, 2011 |
| Total liabilities | $6.68 million | $6.46 million at Dec. 31, 2011 |
Cash plus short-term investments totaled approximately $24.6 million at quarter-end. Net loss increased year over year, principally because Q1 2011 included $2.0 million in Yakult licensing revenue and Q1 2012 operating expenses were higher. The 2012 loss per share was lower despite the larger net loss, reflecting a much higher weighted-average share count (33.2 million versus 13.5 million). No operating margin is meaningful for Q1 2012 because there was no revenue. The company reported an accumulated deficit of $130.5 million. Debt was limited to $135,548 of capital lease obligations, including $78,407 current.
Business developments, outlook and risks
- ThermoDox was in a Phase III trial for primary liver cancer (HEAT), a Phase II trial for colorectal liver metastases (ABLATE), and a Phase I/II trial for recurrent chest wall breast cancer. The HEAT study’s final analysis was projected for late 2012 after the required 380 progression-free-survival events; the 2011 interim review recommended continuing the trial.
- The filing reported that enrollment of at least 200 Chinese patients in HEAT, needed for a China registration filing, was completed and announced April 23, 2012. Japan enrollment remained on hold pending Japanese regulatory guidance; the company said the conditional second $2.0 million Yakult payment had not been earned.
- A May 7, 2012 supply agreement with Zhejiang Hisun covered ThermoDox production in China. Celsion expected to repay approximately $2.0 million in development costs after successful completion of three registration batches, then expected in mid-2013; repayment was due no later than four years after signing.
- Management expected significant operating losses to continue and said substantial additional capital would be needed for development, manufacturing and commercialization. There was no committed financing, and the company warned that it might need dilutive financing, reduce or delay programs, or relinquish product or technology rights if capital was unavailable. The filing provided no specific revenue, earnings, cash-burn or financing guidance.
- Key risks included clinical-trial failure or delay, regulatory approval uncertainty, reliance on third parties for trials and manufacturing, limited revenue sources, capital needs, and the possibility of dilution. The company had no internal sales or marketing capability. It reported disclosure controls effective at a reasonable-assurance level and no material change in internal controls during the quarter.
Most important facts for investors to verify
- Whether the HEAT trial reached its planned final analysis and what the results showed; the late-2012 timing was management’s projection in this filing, not a guarantee.
- Current cash, investment balances, operating cash burn, and financing availability relative to the company’s stated need for substantial additional capital.
- The status of Japan enrollment and the conditional Yakult milestone payment, as well as any changes to licensing economics.
- Whether the Hisun manufacturing arrangement met its milestones and the timing and amount of Celsion’s expected repayment obligation.
- The filing’s cover page appears to mark “No” for having filed all required reports during the preceding 12 months; verify the original SEC filing and the company’s filing-compliance status.